For patients with neovascular age-related macular degeneration (nAMD) who weren't responding well to aflibercept, switching to faricimab appears to be a game-changer. A UK retrospective study tracking 133 eyes over nearly three years found that the switch led to sustained anatomical improvements, fewer injections, and stable vision — a meaningful win for a tough-to-treat population.

After switching, patients followed a personalized treat-and-extend approach. Retinal fluid — a key marker of disease activity — cleared up significantly, and the average time between injections nearly doubled. Serious eye-related complications were rare across nearly 2,700 injections.

By the Numbers:

• Mean central subfield thickness dropped from 304.7 µm to 219.5 µm at year 3 (P < .001)
• Complete resolution of both intraretinal and subretinal fluid jumped from 10.5% to 55.6%
• Average treatment interval extended from 5.8 weeks to 11.5 weeks (P < .001)
• 45.9% of eyes reached intervals of ≥12 weeks by final follow-up
• Only 4 eyes (3%) experienced adverse events across 2,696 injections

Why it matters: For patients stuck on frequent injections with persistent fluid, this data suggests faricimab could offer a real path to better disease control and fewer clinic visits — improving quality of life without sacrificing vision.